Multiple independent data sources confirm the rise is real, not a myth.
US health records showed the diagnosis rate for women aged 30-49 nearly doubled between 2020 and 2022, and prescription claims data show similar increases in the same age band across 2020-2021. Researchers are honest that this documents a change in diagnostic behavior, not necessarily a change in how common ADHD actually is at midlife - the numbers cannot on their own distinguish overdue recognition of ADHD in women, pandemic-era changes in telehealth access, and overdiagnosis. UK data also show women's diagnosed ADHD prevalence remains far below men's, consistent with a large group of women who were simply missed as girls. The honest answer is that all of these forces are probably operating together, and no dataset yet tells us how much of the surge belongs to each.
The debate is whether the surge mainly reflects overdue recognition of lifelong ADHD in women, overdiagnosis fueled by online awareness and pandemic-era telehealth prescribing, or a mix that current data cannot separate.
What the research shows, and which source each finding rests on
US electronic health records covering 3,389,383 people diagnosed with ADHD between 2010 and 2022 found the percentage of women newly diagnosed at ages 30-49 rose from 0.34% (2020) to 0.64% (2022), and the male-to-female diagnosis gap narrowed from men being 133% more likely to be diagnosed in 2010 to 28% more likely in 2022.
US commercial prescription claims data (2016-2021) show single-year 2020-2021 increases in stimulant fills among women aged 35-39 (17.5%) and 40-44 (14.3%), and note that clinical practice guidelines for ADHD exist only for children and adolescents, not adults.
UK primary care data covering 7.66 million people (2000-2018) found adult women's diagnosed ADHD prevalence in 2018 (20 per 10,000) remained far below men's (74.3 per 10,000).
Where the real disagreement is
Each position is shown with its own sources. A position listed here is not necessarily the accepted view.
Overdue recognition
researchers pointing to the historical female diagnostic gap
ADHD was defined and screened around hyperactive boys, so inattentive presentations in girls were missed for decades; a large undiagnosed reservoir of adult women remained even by 2018, so a rising diagnosis rate is overdue correction rather than overdiagnosis.
Overdiagnosis and misattribution
researchers pointing to the coincidence with telehealth and online content
The steepest prescribing rise coincided with pandemic-era telehealth prescribing, over half of the most popular ADHD content online was rated misleading, and because stimulants help menopausal executive complaints even in women without ADHD, a positive response to medication can falsely confirm a wrong diagnosis.
What would settle it: Longitudinal cohorts with childhood-history ascertainment and repeated objective cognitive measures through the transition, which would show what fraction of new diagnoses reflect truly lifelong ADHD versus other explanations.
What is really going on here
- What fraction of new midlife diagnoses would survive structured assessment with childhood ascertainment - unknown.
- How much of the rise reflects pandemic-era telehealth access changes versus genuine recognition - undetermined by current datasets.
Questions for your doctor
- Can we look at whether attention symptoms were present in childhood or school records, not just recently?
- What assessment process will we use beyond a symptom checklist?
- If stimulant treatment helps, how will we interpret that given it can help focus in people without ADHD too?
Questions with no answer yet
How much of the recent rise in diagnoses reflects overdue recognition of lifelong ADHD in women versus overdiagnosis fueled by pandemic-era telehealth prescribing and online awareness?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: Rising diagnosis and prescribing rates document a change in diagnostic behavior, not necessarily a change in prevalence, and the datasets that show the rise cannot on their own distinguish recognition catch-up, telehealth-era access changes, and overdiagnosis from one another.
What would test it: A study design able to separate these forces, such as comparing diagnosis rates and structured-assessment outcomes across periods or regions with differing telehealth access.
What fraction of women newly diagnosed with ADHD in midlife would keep that diagnosis after a full structured assessment that checks for childhood onset?
Not directly studied yetNo research does not mean it does not work, and it does not mean it works. It means nobody has tested it yet.
What is known: This is named as an explicit open question in this area; the entire peer-reviewed literature on ADHD and female sex hormones comprised only 11 studies as of a recent systematic search, none directly on menopause.
What would test it: A study applying structured childhood-onset ascertainment to a cohort of women newly diagnosed with ADHD in midlife.
Sources
- 1.Epic Research, Number of ADHD Patients Rising Especially Among Women, 2023-03-30Review, opinion or mechanism
- 2.Trends in Stimulant Prescription Fills Among Commercially Insured Children and Adults - United States, 2016-2021.Danielson ML et al., MMWR Morb Mortal Wkly Rep 2023;72(13):327-332 · Comparative or small study
- 3.Attention-deficit hyperactivity disorder diagnoses and prescriptions in UK primary care, 2000-2018: population-based cohort study.McKechnie DGJ et al., BJPsych Open 2023;9(4):e121 · Observational study
- 4.TikTok and Attention-Deficit/Hyperactivity Disorder: A Cross-Sectional Study of Social Media Content Quality.Yeung A et al., Can J Psychiatry 2022;67(12):899-906 · Comparative or small study
- 5.Integrative literature review - the impact of ADHD across women's lifespan.Krebs K, Donnellan-Fernandez R, BMC Womens Health 2025;25:593 · Observational study
The letter grades the type of study behind a claim, not the answer itself.
This page is general information based on published research and public sources. It is not medical advice and not a personal assessment, and it does not replace a conversation with your doctor. Peritale is a wellness product, not a medical device, and is not intended to diagnose, treat, cure or prevent any disease. For any medical question, speak with a licensed clinician.
You are not imagining it
In about seven minutes on your phone, Peritale reads five signal systems and maps your symptoms, so you can see that what you feel is real, follow your hormonal transition over time, and walk into your doctor ready to ask for the care you deserve. Your first check is free, no credit card.
Start Free MappingRelated questions
- How do I know if it's ADHD or just perimenopause brain fog?
- The stimulant medication helped me focus - doesn't that prove I have ADHD?
- Can perimenopause make an autoimmune condition flare up or get worse?
- Can I take hormone therapy if I have lupus?
- Does hormone therapy help or hurt rheumatoid arthritis around menopause?
- Does menopause make multiple sclerosis worse?
- Back to topic: ADHD, autoimmune conditions and histamine